Published in J Interferon Res on December 01, 1992
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
FOUR RECENT INFLUENZA EPIDEMICS: AN EXPERIMENTAL STUDY. J Clin Invest (1940) 20.40
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
A roadmap for graphene. Nature (2012) 8.66
A LATENT VIRUS IN NORMAL MICE CAPABLE OF PRODUCING PNEUMONIA IN ITS NATURAL HOST. J Exp Med (1940) 8.58
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol (1998) 5.01
Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol (1996) 4.92
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med (2001) 4.50
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med (1992) 4.33
Excision of deoxyribose phosphate residues by DNA polymerase beta during DNA repair. Science (1995) 4.22
Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR Mycobacterium tuberculosis PCR test. J Clin Microbiol (1995) 4.11
Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature (1985) 4.02
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA (1994) 4.01
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol (2001) 3.44
Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab (2001) 3.43
A functional imaging study of cooperation in two-person reciprocal exchange. Proc Natl Acad Sci U S A (2001) 3.41
Association between air pollution and low birth weight: a community-based study. Environ Health Perspect (1997) 3.32
Risk of internal cancers from arsenic in drinking water. Environ Health Perspect (2000) 3.29
Peroxiredoxin, a novel family of peroxidases. IUBMB Life (2001) 2.91
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med (1986) 2.70
Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem (1998) 2.66
Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc Natl Acad Sci U S A (2001) 2.62
DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep (1976) 2.59
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Papillary cystic and solid tumors of the pancreas: a pancreatic embryonic tumor? Studies of three cases and cumulative review of the world's literature. Surgery (1995) 2.50
Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol (2000) 2.49
Analysis of repeated categorical data using generalized estimating equations. Stat Med (1994) 2.44
Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. EMBO Rep (2001) 2.43
Proliferating cell nuclear antigen-dependent abasic site repair in Xenopus laevis oocytes: an alternative pathway of base excision DNA repair. Mol Cell Biol (1994) 2.42
Down syndrome and thyroid function in adults. Lancet (1975) 2.39
In vitro inhibition of diphtheria toxin action by ammonium salts and amines. J Bacteriol (1965) 2.38
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis (1998) 2.27
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol (1999) 2.22
Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res (2000) 2.15
Survival analysis in natural history studies of disease. Stat Med (1989) 2.11
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J Biol Chem (1993) 2.04
Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J Biol Chem (2000) 2.04
Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol (1991) 2.03
Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. J Clin Oncol (1989) 2.02
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum. Mol Biochem Parasitol (1996) 2.02
Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Proc Natl Acad Sci U S A (1999) 2.02
Extraskeletal myxoid chondrosarcoma. An analysis of 34 cases. Hum Pathol (1972) 2.00
Multiple trace theory of human memory: computational, neuroimaging, and neuropsychological results. Hippocampus (2000) 1.97
The prenatal detection of significant alcohol exposure with maternal blood markers. J Pediatr (1998) 1.96
Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. J Control Release (2001) 1.94
DNA damage in human sperm is related to urinary levels of phthalate monoester and oxidative metabolites. Hum Reprod (2006) 1.94
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol (1991) 1.91
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am (2006) 1.89
The development and biology of bradyzoites of Toxoplasma gondii. Front Biosci (2000) 1.84
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med (1988) 1.82
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet (2004) 1.79
Mode of inhibition of diphtheria toxin by ammonium chloride. J Bacteriol (1965) 1.79
Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int (2013) 1.79
Treatment of the patient with adenocarcinoma of unknown origin. Cancer (1972) 1.79
Nonenzymatic cleavage of proteins by reactive oxygen species generated by dithiothreitol and iron. J Biol Chem (1985) 1.78
The final stages of spliceosome maturation require Spp2p that can interact with the DEAH box protein Prp2p and promote step 1 of splicing. RNA (1995) 1.77
Complications of cancer immunotherapy with levamisole. Lancet (1977) 1.76
An assay for the mitogenic activity of phytohemagglutinin preparations. Blood (1965) 1.73
Postoperative chemoradiotherapy for gastric cancer. Ann Oncol (2003) 1.73
Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology (1990) 1.72
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71
HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol (1995) 1.71
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Cloning of an intracellular Poly[D(-)-3-Hydroxybutyrate] depolymerase gene from Ralstonia eutropha H16 and characterization of the gene product. J Bacteriol (2001) 1.70
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol (1989) 1.69
Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. J Control Release (2003) 1.69
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
Orbit, a novel microtubule-associated protein essential for mitosis in Drosophila melanogaster. J Cell Biol (2000) 1.66
Malignant pulmonary neoplasms predisposing to spontaneous pneumothorax. Mayo Clin Proc (1973) 1.66
The pulmonary toxicity of antineoplastic agents. Semin Oncol (1982) 1.65
Volume kinetics of Ringer solution, dextran 70, and hypertonic saline in male volunteers. Anesthesiology (1997) 1.64
Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Korea during 2000. Arch Virol (2003) 1.64
Outbreaks of diarrhea associated with Clostridium difficile and its toxin in day-care centers: evidence of person-to-person spread. J Pediatr (1983) 1.63
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61